Alterations of retinal vasculature in cystathionine-beta-synthase mutant mice, a model of hyperhomocysteinemia

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 939-949

  Tawfik, Amany ^a   Al Shabrawey, Mohamed ^a   Roon, Penny ^a   Sonne, Srinivas ^b   Covar, Jason A ^a   Matragoon, Surapoon ^a   Ganapathy, Preethi S ^a   Atherton, Sally S ^a   El Remessy, Azza ^a   Ganapathy, Vadivel ^a,b   Smith, Sylvia B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; ENDOGLIN; HOMOCYSTEINE; ISOLECTIN B4; OCCLUDIN; PROTEIN ZO1; TRYPSIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GLIOSIS; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA FLUORESCEIN ANGIOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CYSTATHIONINE BETA-SYNTHASE; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GENE EXPRESSION REGULATION; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; IMMUNOHISTOCHEMISTRY; MICE; MICE, MUTANT STRAINS; MICROSCOPY, FLUORESCENCE; RETINA; RETINAL DISEASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873371829     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10536     Document Type: Article

References (41)

1. Perła-Kaján J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007;32:561-572.
2. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: a review. Am J Med Genet C Semin Med Genet. 2011; 157:3-32.
3. Bleich S, Jünemann A, Von Ahsen N, et al. Homocysteine and risk of open-angle glaucoma. J Neural Transm. 2002;109: 1499-1504.
4. Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol. 2003;136:41-46.
5. Jaksic V, Markovic V, Milenkovic S, Stefanovic I, Jakovic N, Knezevic M. MTHFR C677T homozygous mutation in a patient with pigmentary glaucoma and central retinal vein occlusion. Ophthalmic Res. 2010;43:193-196.
6. Axer-Siegel R, Bourla D, Ehrlich R, et al. Association of neovascular age-related macular degeneration and hyperhomocysteinemia. Am J Ophthalmol. 2004;137:84-89.
7. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. Am J Ophthalmol. 2006;141:201-203.
8. Tsina EK, Marsden DL, Hansen RM, Fulton AB. Maculopathy and retinal degeneration in cobalamin C methylmalonic aciduria and homocystinuria. Arch Ophthalmol. 2005;123: 1143-1146.
9. Aydemir O, Türkçüoǧlu P, Güler M, et al. Plasma and vitreous homocysteine concentrations in patients with proliferative diabetic retinopathy. Retina. 2008;28:741-743.
10. Yang G, Lu J, Pan C. The impact of plasma homocysteine level on development of retinopathy in type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi. 2002;41:34-38.
11. Semba RD. Retinal vascular disease. In: Nutrition and Health: Handbook of Nutrition and Ophthalmology. Totowa, NY: Humana Press; 2007:257-280.
12. Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med. 2003;9: 385-392.
13. Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB. Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1-specific ligand. Invest Ophthamol Vis Sci. 2007;48:4785-4794.
14. Ganapathy PS, Dun Y, Ha Y, et al. Sensitivity of staurosporineinduced differentiated RGC-5 cells to homocysteine. Curr Eye Res. 2010;35:80-90.
15. Moore P, El-sherbeny A, Roon P, Schoenlein PV, Ganapathy V, Smith SB. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res. 2001;73:45-57.
16. Chang HH, Lin DP, Chen YS, et al. Intravitreal homocysteinethiolactone injection leads to the degeneration of multiple retinal cells, including photoreceptors. Mol Vis. 2011;17: 1946-1956.
17. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocysteinemia. Proc Natl Acad Sci. U S A. 1995;92:1585-1589.
18. Ganapathy PS, Moister B, Roon P. Endogenous elevation of homocysteine induces retinal neuron death in the cystathionine-beta-synthase mutant mouse. Invest Ophthalmol Vis Sci. 2009;50:4460-4470.
19. Ganapathy PS, Perry RL, Tawfik A. Homocysteine-mediated modulation of mitochondrial dynamics in retinal ganglion cells. Invest Ophthalmol Vis Sci. 2011;52:5551-5558.
20. Yu M, Sturgill-Short G, Ganapathy P, Tawfik A, Peachey NS, Smith SB. Age-related changes in visual function in cystathionine-beta-synthase mutant mice, a model of hyperhomocysteinemia. Exp Eye Res. 2012;96:124-131.
21. Ha Y, Saul A, Tawfik A. Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1). Invest Ophthalmol Vis Sci. 2011;52:7749-7760.
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.
23. Stitt AW, Li YM, et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150:523-531.
24. Yang J, Duh EJ, Caldwell RB, Behzadian MA. Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/ beta-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci. 2010;51:3273-3280.
25. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets. 2003;3:427-432.
26. Nassiri F, Cusimano MD, Scheithauer BW, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 2011;31: 2283-2290.
27. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retina Eye Res. 2008;27:331-371.
28. Lewis GP, Fisher SK. Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. Int Rev Cytol. 2003;230:263-290.
29. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10:103-117.
30. Jiang X, Yang F, Tan H, et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol. 2005;25:2515-2521.
31. Baumbach GL, Sigmund CD, Bottiglieri T, Lentz SR. Structure of cerebral arterioles in cystathionine β-synthase-deficient mice. Circ Res. 2002;91:931-937.
32. Bosch-Marce M, Pola R, Wecker AB, et al. Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. Vasc Med. 2005;10:15-22.
33. Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood. 2006;107:591-593.
34. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
35. Andersson HC, Marble M, Shapira E. Long-term outcome in treated combined methylmalonic acidemia and homocystinemia. Genet Med. 1999;1:146-150.
36. Taylor RH, Burke J, O'Keefe M, Beighi B, Naughton E. Ophthalmic abnormalities in homocystinuria: the value of screening. Eye (Lond). 1998;12:427-430.
37. Juszko J, Kubalska J, Kanigowska K. Ocular problems in children with homocystinuria. Klin Oczna. 1994;96:212-215.
38. Oosterbaan AM, Steegers EA, Ursem NT. The effects of homocysteine and folic acid on angiogenesis and VEGF expression during chicken vascular development. Microvasc Res. 2012;83:98-104.
39. Beard RS Jr, Bearden SE. Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research. Am J Physiol Heart Circ Physiol. 2011;300:H13-26.
40. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond). 2011;121:459-488.
41. Lawrance AK, Racine J, Deng L, Wang X, Lachapelle P, Rozen R. Complete deficiency of methylenetetrahydrofolate reductase in mice is associated with impaired retinal function and variable mortality, hematological profiles, and reproductive outcomes. J Inherit Metab Dis. 2011;34:147-157.